Compare HOV & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOV | CRVS |
|---|---|---|
| Founded | 1959 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.5M | 546.7M |
| IPO Year | N/A | 2016 |
| Metric | HOV | CRVS |
|---|---|---|
| Price | $120.80 | $6.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $120.00 | $13.75 |
| AVG Volume (30 Days) | 104.4K | ★ 1.7M |
| Earning Date | 02-23-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.43 | N/A |
| Revenue | ★ $2,978,581,000.00 | N/A |
| Revenue This Year | $7.30 | N/A |
| Revenue Next Year | $4.88 | N/A |
| P/E Ratio | $16.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $81.15 | $2.54 |
| 52 Week High | $162.06 | $9.60 |
| Indicator | HOV | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 64.33 | 36.31 |
| Support Level | $97.03 | $6.45 |
| Resistance Level | $101.77 | $7.18 |
| Average True Range (ATR) | 4.63 | 0.46 |
| MACD | 2.15 | -0.08 |
| Stochastic Oscillator | 93.70 | 20.06 |
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).